Evaluation of the Usefulness of a Treat and Extend Regimen Using Ranibizumab for Neovascular AMD.

Sponsor
Nagoya City University
Study ID
NCT02321839
Phase
PHASE4
Status
Completed

Conditions

  • Neovascular Age-related Macular Degeneration

Eligibility Criteria

Sex
ALL
Age
50 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

To evaluate the visual outcome, number of injections and visits, and the effect of mental status of a treat and extend regimen in managing neovascular age-related macular degeneration with intravitreal ranibizumab.

Key Dates

First listed
Dec 22, 2014
Start date
Jan 31, 2014
Status verified
Oct 2016
Primary completion
Mar 31, 2019
Completion
Mar 31, 2019

Study Design

Enrollment
78 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Intraviteal Ranibizumab 0.5mg
    Intraviteal Ranibizumab 0.5mg

Primary Outcome Measure

Visual acuity [ Time Frame: One Year ]

Related Studies